156 related articles for article (PubMed ID: 11751474)
21. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.
Hua Z; Zhang YC; Hu XM; Jia ZG
World J Gastroenterol; 2003 Dec; 9(12):2764-7. PubMed ID: 14669329
[TBL] [Abstract][Full Text] [Related]
22. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts.
Argani P; Shaukat A; Kaushal M; Wilentz RE; Su GH; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
Cancer; 2001 Apr; 91(7):1332-41. PubMed ID: 11283934
[TBL] [Abstract][Full Text] [Related]
23. [The effects of transferring DPC4-adenovirus on pancreatic adenocarcinoma cells].
Feng XL; Zhang ZD; Tian L; Wei YQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 35(5):607-11. PubMed ID: 15460398
[TBL] [Abstract][Full Text] [Related]
24. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct.
Tascilar M; Offerhaus GJ; Altink R; Argani P; Sohn TA; Yeo CJ; Cameron JL; Goggins M; Hruban RH; Wilentz RE
Am J Clin Pathol; 2001 Dec; 116(6):831-7. PubMed ID: 11764071
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
Murphy KM; Brune KA; Griffin C; Sollenberger JE; Petersen GM; Bansal R; Hruban RH; Kern SE
Cancer Res; 2002 Jul; 62(13):3789-93. PubMed ID: 12097290
[TBL] [Abstract][Full Text] [Related]
27. Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-associated neoplasms.
Lei J; Zou TT; Shi YQ; Zhou X; Smolinski KN; Yin J; Souza RF; Appel R; Wang S; Cymes K; Chan O; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1996 Dec; 13(11):2459-62. PubMed ID: 8957088
[TBL] [Abstract][Full Text] [Related]
28. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis.
van Heek T; Rader AE; Offerhaus GJ; McCarthy DM; Goggins M; Hruban RH; Wilentz RE
Am J Clin Pathol; 2002 May; 117(5):755-65. PubMed ID: 12090425
[TBL] [Abstract][Full Text] [Related]
29. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
[TBL] [Abstract][Full Text] [Related]
30. Smad4 deficiency in cervical carcinoma cells.
Baldus SE; Schwarz E; Lohrey C; Zapatka M; Landsberg S; Hahn SA; Schmidt D; Dienes HP; Schmiegel WH; Schwarte-Waldhoff I
Oncogene; 2005 Jan; 24(5):810-9. PubMed ID: 15531914
[TBL] [Abstract][Full Text] [Related]
31. Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors.
Stancu M; Wu TT; Wallace C; Houlihan PS; Hamilton SR; Rashid A
Mod Pathol; 2003 Dec; 16(12):1189-98. PubMed ID: 14681318
[TBL] [Abstract][Full Text] [Related]
32. Two novel polymorphisms, c1086T>C and c1798C>T, in the MADH4/DPC4 gene.
Moore PS; Rigaud G; Baron A; Scarpa A
Hum Mutat; 2000 May; 15(5):485-6. PubMed ID: 10790223
[No Abstract] [Full Text] [Related]
33. DPC4/SMAD4 gene alterations in human cancer, and their functional implications.
Schutte M
Ann Oncol; 1999; 10 Suppl 4():56-9. PubMed ID: 10436786
[TBL] [Abstract][Full Text] [Related]
34. The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome.
Toga T; Nio Y; Hashimoto K; Higami T; Maruyama R
Anticancer Res; 2004; 24(2C):1173-8. PubMed ID: 15154643
[TBL] [Abstract][Full Text] [Related]
35. [Genetics of pancreatic cancer: recent advances in molecular diagnosis].
Hayashi N; Egami H; Ogawa M
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):476-81. PubMed ID: 12094699
[TBL] [Abstract][Full Text] [Related]
36. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis.
Jonckheere N; Perrais M; Mariette C; Batra SK; Aubert JP; Pigny P; Van Seuningen I
Oncogene; 2004 Jul; 23(34):5729-38. PubMed ID: 15184872
[TBL] [Abstract][Full Text] [Related]
37. The 18q21 region in colorectal and pancreatic cancer: independent loss of DCC and DPC4 expression.
Barberá VM; Martín M; Mariñoso L; Munné A; Carrato A; Real FX; Fabre M
Biochim Biophys Acta; 2000 Oct; 1502(2):283-96. PubMed ID: 11040453
[TBL] [Abstract][Full Text] [Related]
38. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.
Salek C; Minarikova P; Benesova L; Nosek V; Strnad R; Zavoral M; Minarik M
Anticancer Res; 2009 May; 29(5):1803-10. PubMed ID: 19443408
[TBL] [Abstract][Full Text] [Related]
39. Ampulla of vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis.
Beghelli S; Orlandini S; Moore PS; Talamini G; Capelli P; Zamboni G; Falconi M; Scarpa A
Virchows Arch; 2002 Jul; 441(1):19-24. PubMed ID: 12111196
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer.
Hao J; Zhang S; Zhou Y; Liu C; Hu X; Shao C
Biochem Biophys Res Commun; 2011 Mar; 406(4):552-7. PubMed ID: 21352803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
